

Amendment to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. Canceled.


2. Canceled.

3. (Previously presented) A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisindoline-4-yl}carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate thereof.

4. (Previously presented) A method of treating chronic uveitis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisindoline-4-yl}carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate thereof, and a therapeutically effective amount of a second active ingredient.

5. Canceled.
6. Canceled.
7. Canceled.
8. (Currently amended) The method of claim 4, wherein the second active ingredient is ~~hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, corticosteroid, or a pharmacologically active mutant or derivative thereof,~~ or a combination thereof.
9. (Currently amended) The method of claim ~~8~~ 4, wherein the second active ingredient is oblimersen, melphalan, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, taxotere, irinotecan, a COX-2 inhibitor, ciprofloxacin, dexamethasone, doxorubicin, vincristine, IL 2, IFN, dacarbazine, Ara-C, vinorelbine, isotretinoin, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, ~~or a pharmacologically active mutant or derivative thereof,~~ or a combination thereof.
10. Canceled.
11. (Previously presented) The method of claim 3 or 4, wherein the compound is enantiomerically pure.
- 12 – 24. Canceled.
25. (Previously presented) The method according to claim 3 or 4, wherein the compound is administered in an amount of from about 1 to about 10,000 mg per day.
- 26 – 32. Canceled.
33. (Previously presented) The method of claim 25, wherein the compound is administered in an amount of about 10, 25, 50, 100, 200 or 300 mg per day.
34. (Previously presented) The method of claim 25, wherein the compound is orally administered.
35. (Previously presented) The method of claim 25, wherein the compound is administered in a capsule.

36. (Previously presented) The method of claim 35, wherein the compound is administered in 50 mg or 100 mg of a capsule.

37. (Previously presented) The method of claim 25, wherein the compound is topically administered.

38. (Previously presented) The method of claim 37, wherein the compound is administered in a spray, aerosol, solution, suspension or eye drop.

39. (Previously presented) The method of claim 8, wherein the second active ingredient is prednisone.